Subscribe To
GLUE / Down -56.34% in 4 Weeks, Here's Why You Should You Buy the Dip in Monte Rosa Therapeutics (GLUE)
GLUE News
By Zacks Investment Research
October 24, 2023
Down -56.34% in 4 Weeks, Here's Why You Should You Buy the Dip in Monte Rosa Therapeutics (GLUE)
Monte Rosa Therapeutics (GLUE) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combi more_horizontal
By Zacks Investment Research
January 25, 2023
How Much Upside is Left in Monte Rosa Therapeutics (GLUE)? Wall Street Analysts Think 226.46%
The mean of analysts' price targets for Monte Rosa Therapeutics (GLUE) points to a 226.5% upside in the stock. While this highly sought-after metric h more_horizontal